{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:42Z","timestamp":1792715862647,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Gerontology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.exger.2026.113325","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:01:14Z","timestamp":1789365674000},"page":"113325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension"],"prefix":"10.1016","volume":"225","author":[{"given":"Dana","family":"Al-Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nady","family":"El Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.exger.2026.113325_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.exger.2026.113325_bb0010","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73420","article-title":"DunedinPACE, a DNA methylation biomarker of the pace of aging","volume":"11","author":"Belsky","year":"2022","journal-title":"eLife"},{"issue":"5","key":"10.1016\/j.exger.2026.113325_bb0015","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.exger.2026.113325_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-72861-3","article-title":"Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy","volume":"17","author":"Corley","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.exger.2026.113325_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41514-026-00383-9","article-title":"Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study","volume":"12","author":"Corley","year":"2026","journal-title":"Npj Aging."},{"issue":"7","key":"10.1016\/j.exger.2026.113325_bb0030","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol."},{"issue":"10544","key":"10.1016\/j.exger.2026.113325_bb0035","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(26)00459-9","article-title":"Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials","volume":"407","author":"Cummings","year":"2026","journal-title":"Lancet"},{"issue":"10454","key":"10.1016\/j.exger.2026.113325_bb0040","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"SELECT trial investigators. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.exger.2026.113325_bb0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13105-022-00939-9","article-title":"Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts","volume":"79","author":"Durak","year":"2023","journal-title":"J. Physiol. Biochem."},{"issue":"9","key":"10.1016\/j.exger.2026.113325_bb0050","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215840120","article-title":"Epigenetic-based age acceleration in a representative sample of older Americans: associations with aging-related morbidity and mortality","volume":"120","author":"Faul","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.exger.2026.113325_bb0055","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.17891","article-title":"Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice","volume":"12","author":"Feng","year":"2024","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.exger.2026.113325_bb0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13148-019-0790-2","article-title":"The effects of bariatric surgery on clinical profile, DNA methylation, and ageing in severely obese patients","volume":"12","author":"Fraszczyk","year":"2020","journal-title":"Clin. Epigenetics"},{"issue":"10193","key":"10.1016\/j.exger.2026.113325_bb0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"REWIND investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.exger.2026.113325_bb0070","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cmet.2023.12.007","article-title":"Human trials exploring anti-aging medicines","volume":"36","author":"Guarente","year":"2024","journal-title":"Cell Metab."},{"issue":"10157","key":"10.1016\/j.exger.2026.113325_bb0075","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Harmony outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.exger.2026.113325_bb0080","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s13577-024-01038-1","article-title":"Liraglutide prevents cellular senescence in human retinal endothelial cells (HRECs) mediated by SIRT1: an implication in diabetic retinopathy","volume":"37","author":"Hou","year":"2024","journal-title":"Hum. Cell"},{"issue":"12","key":"10.1016\/j.exger.2026.113325_bb0085","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.cmet.2025.10.014","article-title":"Body-wide multi-omic counteraction of aging with GLP-1R agonism","volume":"37","author":"Huang","year":"2025","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.exger.2026.113325_bb0090","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"PIONEER 6 investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.exger.2026.113325_bb0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"SURMOUNT-1 investigators. Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exger.2026.113325_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1380476","article-title":"The potential of short-chain fatty acid epigenetic regulation in chronic low-grade inflammation and obesity","volume":"15","author":"Kopczy\u0144ska","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.exger.2026.113325_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13818","article-title":"Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: current and future potentials","volume":"22","author":"Kreiner","year":"2023","journal-title":"Aging Cell"},{"issue":"4","key":"10.1016\/j.exger.2026.113325_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13596","article-title":"Geroscience-guided repurposing of FDA-approved drugs to target aging: a proposed process and prioritization","volume":"21","author":"Kulkarni","year":"2022","journal-title":"Aging Cell"},{"issue":"24","key":"10.1016\/j.exger.2026.113325_bb0115","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"SELECT trial investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.exger.2026.113325_bb0120","first-page":"9484","article-title":"DNA methylation GrimAge version 2","volume":"14","author":"Lu","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"19","key":"10.1016\/j.exger.2026.113325_bb0125","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.025545","article-title":"Racial and ethnic disparities in financial barriers among overweight and obese adults eligible for semaglutide in the United States","volume":"11","author":"Lu","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"10.1016\/j.exger.2026.113325_bb0130","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s43587-023-00416-y","article-title":"Targeting the biology of aging with mTOR inhibitors","volume":"3","author":"Mannick","year":"2023","journal-title":"Nat. Aging"},{"issue":"4","key":"10.1016\/j.exger.2026.113325_bb0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER steering committee and LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.exger.2026.113325_bb0140","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.exger.2026.113325_bb0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bioe.13129","article-title":"Healthspan extension, completeness of life and justice","volume":"37","author":"Masny","year":"2023","journal-title":"Bioethics"},{"issue":"12","key":"10.1016\/j.exger.2026.113325_bb0150","doi-asserted-by":"crossref","first-page":"E859","DOI":"10.1001\/amajethics.2025.859","article-title":"Should clinicians be agents of anti-aging?","volume":"27","author":"McKiddy","year":"2025","journal-title":"AMA J. Ethics"},{"issue":"2","key":"10.1016\/j.exger.2026.113325_bb0155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation","volume":"42","author":"McLean","year":"2021","journal-title":"Endocr. Rev."},{"issue":"7","key":"10.1016\/j.exger.2026.113325_bb0160","doi-asserted-by":"crossref","DOI":"10.1111\/acel.14175","article-title":"Association between epigenetic age and type 2 diabetes mellitus or glycemic traits: a longitudinal twin study","volume":"23","author":"Miao","year":"2024","journal-title":"Aging Cell"},{"issue":"9","key":"10.1016\/j.exger.2026.113325_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanhl.2024.08.001","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?","volume":"5","author":"Mone","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.exger.2026.113325_bb0170","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/s41587-025-02932-1","article-title":"Are GLP-1s the first longevity drugs?","volume":"43","author":"Nature Biotechnology Editorial","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.exger.2026.113325_bb0175","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement (N Y)."},{"key":"10.1016\/j.exger.2026.113325_bb0180","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s42255-024-01191-9","article-title":"Short-chain fatty acid metabolites propionate and butyrate are unique epigenetic regulatory elements linking diet, metabolism and gene expression","volume":"7","author":"Nshanian","year":"2025","journal-title":"Nat. Metab."},{"key":"10.1016\/j.exger.2026.113325_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102582","article-title":"Semaglutide as a possible therapy for healthy aging: targeting the hallmarks of aging","volume":"102","author":"Ortiz","year":"2024","journal-title":"Ageing Res. Rev."},{"issue":"12","key":"10.1016\/j.exger.2026.113325_bb0190","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.3390\/cimb46120872","article-title":"Spotlight on the mechanism of action of semaglutide","volume":"46","author":"Papakonstantinou","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"10","key":"10.1016\/j.exger.2026.113325_bb0195","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s43587-023-00489-9","article-title":"Combinatorial interventions in aging","volume":"3","author":"Parkhitko","year":"2023","journal-title":"Nat. Aging"},{"issue":"2","key":"10.1016\/j.exger.2026.113325_bb0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"FLOW trial investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.exger.2026.113325_bb0205","doi-asserted-by":"crossref","first-page":"16489","DOI":"10.1096\/fj.202000860RR","article-title":"Incretin drugs effect on epigenetic machinery: new potential therapeutic implications in preventing vascular diabetic complications","volume":"34","author":"Scisciola","year":"2020","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.exger.2026.113325_bb0210","article-title":"The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity","volume":"6","author":"Scragg","year":"2025","journal-title":"Med (Cell Press)."},{"issue":"4","key":"10.1016\/j.exger.2026.113325_bb0215","doi-asserted-by":"crossref","DOI":"10.1111\/acel.14101","article-title":"Alterations of the gut microbiome are associated with epigenetic age acceleration and physical fitness","volume":"23","author":"Torma","year":"2024","journal-title":"Aging Cell"},{"key":"10.1016\/j.exger.2026.113325_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101737","article-title":"Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3)","volume":"55","author":"Verma","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.exger.2026.113325_bb0225","first-page":"248","article-title":"Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial","volume":"3","author":"Waziry","year":"2023","journal-title":"Nat. Aging"},{"issue":"1","key":"10.1016\/j.exger.2026.113325_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010065","article-title":"GLP-1 receptor agonists\u2014effects beyond obesity and diabetes","volume":"13","author":"Wilbon","year":"2024","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.exger.2026.113325_bb0235","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"STEP 1 study group. Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.exger.2026.113325_bb0240","doi-asserted-by":"crossref","first-page":"E866","DOI":"10.1001\/amajethics.2025.866","article-title":"Lessons for responsible geroscience from the history of longevity","volume":"27","author":"Wohns","year":"2025","journal-title":"AMA J. Ethics"},{"issue":"21","key":"10.1016\/j.exger.2026.113325_bb0245","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1\u2013based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.exger.2026.113325_bb0250","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40520-024-02877-6","article-title":"Gut microbiota and epigenetic age acceleration: a bi-directional Mendelian randomization study","volume":"36","author":"Xu","year":"2024","journal-title":"Aging Clin. Exp. Res."},{"issue":"22","key":"10.1016\/j.exger.2026.113325_bb0255","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1016\/j.cell.2024.08.021","article-title":"Metformin decelerates aging clock in male monkeys","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.exger.2026.113325_bb0260","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02032-23","article-title":"Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases","volume":"15","author":"Zeng","year":"2024","journal-title":"mBio"}],"container-title":["Experimental Gerontology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0531556526003049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0531556526003049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:40:15Z","timestamp":1792712415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0531556526003049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":52,"alternative-id":["S0531556526003049"],"URL":"https:\/\/doi.org\/10.1016\/j.exger.2026.113325","relation":{},"ISSN":["0531-5565"],"issn-type":[{"value":"0531-5565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension","name":"articletitle","label":"Article Title"},{"value":"Experimental Gerontology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exger.2026.113325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113325"}}